Early access of MK0518 [raltegravir] in combination with an optimized background antiretroviral therapy (OBT) in highly treatment experienced HIV-1 infected patients with limited to no treatment options.
Phase of Trial: Phase III
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Antiretrovirals; Raltegravir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms EARMRK
- Sponsors Merck & Co
- 11 May 2007 New trial record.